UroGen Pharma Ltd. (URGN) Stock
URGN has an Alpha Score of 29 out of 100 (poor), computed on Nov 5, 2026 from 2 of 4 sub-scores. Company insiders reported 0 open-market buys and 4 sales on SEC Form 4 in the 90 days to Nov 10, 2026.
What is URGN's Alpha Score?
How it works →Alpha Score of 29 reflects poor overall profile with poor momentum, moderate quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 5, 2026
A rules-based research rating, not a recommendation to buy or sell.
Are UroGen Pharma Ltd. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 8, 26 | Degnan Chris | Chief Financial Officer | SELL | 2.2K | $81K |
| Sep 8, 26 | Smith Jason Drew | General Counsel | SELL | 1.5K | $65K |
| Sep 8, 26 | Schoenberg Mark | Chief Medical Officer | SELL | 871 | $37K |
| Aug 20, 26 | Schoenberg Mark | Chief Medical Officer | SELL | 60.7K | $2.9M |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →What are URGN's key statistics?
Key statistics as of Oct 29, 2026
How does URGN's valuation compare with the Healthcare sector?
| Metric | URGN | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -51.73% | 3.60% | 175 |
| Return on equity | -204.47% | 2.93% | 201 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 11, 2026). P/E excludes loss-making companies.
URGN price chart
Powered by TradingViewWhat does UroGen Pharma Ltd. do?
UroGen Pharma Ltd. is an Israel-based biopharmaceutical company specializing in innovative treatments for urological cancers and diseases. The company develops therapies using its proprietary RTGel reverse-thermal hydrogel technology, a sustained-release platform that enhances drug delivery directly to targeted tissues in the urinary tract. Key FDA-approved products include Jelmyto, a mitomycin-based formulation for low-grade upper tract urothelial cancer, and Zusduri, designed for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. UroGen Pharma Ltd. also advances a pipeline of product candidates like MitoGel (UGN-101) and VesiGel (UGN-102), focusing on chemotherapy agents such as mitomycin C for various bladder and upper tract cancers. This technology addresses limitations of traditional treatments by enabling localized, prolonged exposure while minimizing systemic side effects. Operating in the pharmaceuticals and biotechnology sector, UroGen Pharma Ltd. plays a vital role in uro-oncology by providing non-surgical alternatives and expanding patient access to advanced bladder cancer therapies.